• Christian Probst, Frank Hildebrand, Martijn van Griensven, Hellmut Baur, Lutz Mahlke, Christian Krettek, Hans-Christoph Pape, and Martin Rolf Wolfgang Grotz.
• Department of Trauma Surgery, Hannover Medical School, 30623 Hannover, Germany. probst.christian@mh-hannover.de
• Injury. 2010 May 1; 41 (5): 499-505.

BackgroundThe goal of this prospective, randomised, double-blind clinical trial study was to assess the effects of dopexamine hydrochloride on organ failure, inflammatory mediators and splanchnic oxygenation in blunt multiple trauma patients at high risk of multiple organ dysfunction syndrome (MODS).MethodsWe performed a prospective randomised controlled trial on 30 consecutive blunt multiple trauma patients with ISS>or=16, age 18-60 years and initial blood pressure >or=120 mmHg initially admitted to our level I trauma centre. Patients were randomised to treatment with dopamine (n=15) or dopexamine (n=15) for 48 h after admission. Outcome in terms of mortality, MODS, splanchnic perfusion, complications, duration of stay was statistically analysed.ResultsDopexamine treatment was associated with impaired organ function and an increased duration of ventilation and ICU stay compared with patients who received dopamine treatment. The acute inflammatory response was increased in the Dopexamine group while a decreased pHi and MEGX formation and increased serum lactate levels were measured.ConclusionsThe indication to use dopexamine hydrochloride appears questionable. In the absence of an antiinflammatory effect, dopexamine demonstrated a disadvantageous ICU course in regards to the organ function and the duration of treatment. In addition, a decreased pHi and MEGX formation suggested a deterioration of splanchnic oxygenation.(c) 2009 Elsevier Ltd. All rights reserved.

45 keywords...

hide…